Multicenter, 4-week Crossover (Total Duration 12 Weeks), Placebo-controlled, Double-blind Study to Determine the Impact of QVA149 (Indacaterol/Glycopyrronium) 85/43 µg on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)
Phase of Trial: Phase IV
Latest Information Update: 12 May 2017
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms DuoSleep
- Sponsors Novartis
- 05 May 2017 Status changed from recruiting to completed.
- 13 Sep 2016 This trial has been completed in Sweden (end date: 22 Jun 2016), according to the European Clinical Trials Database.
- 03 Aug 2016 This trial has been completed in Denmark (end date: 22 Jun 2016), according to the European Clinical Trials Database.